Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.82 |
| ▸ | CYSLTR2 | Q9NS75 | 10/20 | 0.81 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | RECQL | P46063 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | EGFR | P00533 | 1/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.81 |
| ▸ | FYN | P06241 | 1/20 | 0.81 |
| ▸ | PGR | P06401 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537796 | 1.00 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL538485 | 1.00 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL12702837 | 1.00 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL30719989 | 1.00 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL8761836 | 1.00 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL3415118 | 0.94 | CYSLTR1 (0.80) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL30719988 | 0.94 | CYSLTR1 (0.80) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL30697130 | 0.94 | CYSLTR1 (0.80) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL29543048 | 0.94 | CYSLTR1 (0.80) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL28103200 | 0.94 | CYSLTR1 (0.80) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248641-A1 | TOPICAL MONTELUKAST FOR TREATMENT OF ATOPIC DERMATITIS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-08-10 | — | — | US | disclosed |
| US-20200237651-A1 | TOPICAL MONTELUKAST FOR TREATMENT OF ATOPIC DERMATITIS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2020-07-30 | — | — | US | disclosed |
| US-10548837-B1 | Topical montelukast for treatment of atopic dermatitis | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2020-02-04 | — | — | US | disclosed |
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | disclosed |
| US-8115004-B2 | Process for pure montelukast sodium through pure intermediates as well as amine salts | MSN LABORATORIES LIMITED (IN) | 2012-02-14 | — | — | US | disclosed |
| EP-2413911-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., Novo Mesto (SI) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112222-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., NOVO MESTO (SI) | 2010-10-07 | — | — | WO | disclosed |
| US-20100056793-A1 | PROCESS FOR PURE MONTELUKAST SODIUM THROUGH PURE INTERMEDIATES AS WELL AS NOVEL AMINE SALTS | MSN LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056793-A1 | PROCESS FOR PURE MONTELUKAST SODIUM THROUGH PURE INTERMEDIATES AS WELL AS NOVEL AMINE SALTS | LTC4S, CMA1, CYSLTR2 | CYSLTR1 4/4885CYSLTR2 3/4885CYP2C8 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.